Asarina Pharma AB (STU:APS) Cash And Cash Equivalents : €0.28 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Cash And Cash Equivalents?

Asarina Pharma AB's quarterly cash and cash equivalents declined from Dec. 2022 (€1.24 Mil) to Jun. 2023 (€0.41 Mil) but then stayed the same from Jun. 2023 (€0.41 Mil) to Dec. 2023 (€0.28 Mil).

Asarina Pharma AB's annual cash and cash equivalents declined from Dec. 2021 (€2.11 Mil) to Dec. 2022 (€1.24 Mil) and declined from Dec. 2022 (€1.24 Mil) to Dec. 2023 (€0.28 Mil).

Asarina Pharma AB Cash And Cash Equivalents Historical Data

The historical data trend for Asarina Pharma AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Cash And Cash Equivalents Chart

Asarina Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

12.36

5.75

2.11

1.24

0.28

Asarina Pharma AB Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															1.55	1.16	1.24	0.41	0.28

Asarina Pharma AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Asarina Pharma AB (STU:APS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Asarina Pharma AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB (STU:APS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

ASAP:Sweden

Address

Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65

Website

https://www.asarinapharma.com

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (STU:APS) Headlines

No Headlines